International Assets Investment Management LLC Takes $21.30 Million Position in BioNTech SE (NASDAQ:BNTX)

International Assets Investment Management LLC purchased a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 17,934 shares of the company's stock, valued at approximately $21,300,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC raised its stake in shares of BioNTech by 21.7% during the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company's stock worth $74,000 after buying an additional 111 shares during the last quarter. Covestor Ltd raised its stake in shares of BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company's stock worth $38,000 after buying an additional 133 shares during the last quarter. Midwest Professional Planners LTD. raised its stake in shares of BioNTech by 7.2% during the 1st quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company's stock worth $293,000 after buying an additional 212 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in BioNTech by 2.3% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company's stock worth $904,000 after purchasing an additional 223 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock worth $43,000 after purchasing an additional 252 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on BNTX shares. Jefferies Financial Group upgraded BioNTech from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. Morgan Stanley upgraded BioNTech from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $93.00 to $145.00 in a research report on Tuesday, September 24th. Hsbc Global Res upgraded BioNTech from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. upgraded BioNTech from an "underweight" rating to a "neutral" rating and lifted their price objective for the stock from $91.00 to $125.00 in a research report on Monday, September 16th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a research report on Thursday, September 19th. Five analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, BioNTech has an average rating of "Moderate Buy" and a consensus price target of $135.54.

BioNTech Trading Up 0.0 %

Shares of NASDAQ:BNTX traded up $0.02 during trading on Wednesday, reaching $114.03. 343,988 shares of the stock were exchanged, compared to its average volume of 780,917. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The firm has a market cap of $27.11 billion, a price-to-earnings ratio of -50.45 and a beta of 0.24. The firm's 50-day moving average price is $108.24 and its 200 day moving average price is $95.36.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The company had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business's revenue was down 23.3% on a year-over-year basis. During the same period last year, the firm posted ($0.86) earnings per share. On average, sell-side analysts anticipate that BioNTech SE will post -3.04 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.